Skip to main content
    C

    Cadrenal Therapeutics, Inc. Common Stock (CVKD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.97
    -0.05 (-4.90%)

    Market Cap: $3.09M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    36%(4/11)
    Avg Surprise
    -147.12%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.94
    Range$-0.94 - $-0.93
    2 analysts
    EPS RevisionsNo revisions (7d)
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.45+35.3%
    60d ago$-2.10+55.5%
    30d ago$-0.65-43.8%
    7d ago$-0.940.0%
    Current$-0.94
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.46
    Range$-0.46 - $-0.45
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.46---
    Sep 26EST
    		-$-0.94---
    Jun 26
    Reported Aug 13
    		$-1.14$-1.16+1.72%Beat+39.0%
    Mar 26
    Reported May 7
    		$-1.04$-1.57+33.76%Beat+50.2%
    Dec 25
    Reported Mar 31
    		$-1.41$-1.21-16.53%Miss+44.7%
    Sep 25
    Reported Nov 10
    		$-1.31$-1.55+15.48%Beat+39.9%
    Jun 25
    Reported Aug 11
    		$-1.87$-1.77-5.65%Miss+16.9%
    Mar 25
    Reported May 8
    		$-2.09$-1.64-27.44%Miss-39.3%
    Dec 24
    Reported Mar 13
    		$-2.55$-0.15-1600.00%Miss-5000.0%
    Sep 24
    Reported Nov 7
    		$-2.18$-1.80-21.11%Miss-2638.7%
    Jun 24
    Reported Aug 7
    		$-2.25$-1.80-25.00%Miss-66.7%
    Mar 24
    Reported May 9
    		$-1.50$-1.35-11.11%Miss+77.3%
    Dec 23
    Reported Mar 11
    		$-0.05$-0.08+37.50%Beat+94.1%
    Sep 23
    Reported Nov 9
    		$-0.08N/AN/ABeat-32.7%
    Jun 23
    Reported Aug 10
    		$-1.35N/AN/ABeat-
    Mar 23
    Reported May 10
    		$-6.62N/AN/ABeat-
    Dec 22
    Reported Mar 29
    		$-0.85$0.00N/AMiss-
    Jun 22
    Reported Sep 22
    		$-0.06$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.20EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-275.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio3.73xQuick Ratio3.73x
    Trading Statistics
    Beta1.95Avg Volume211.63K
    52-Week High$14.2152-Week Low$0.82

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.95
    SMA 20$1.04
    SMA 50$1.32
    SMA 200$4.31
    EMA 10$0.98
    EMA 20$1.04
    EMA 50$1.42
    EMA 200$4.36

    MACD

    Line: -0.11Signal: -0.13Hist: 0.02

    ADX

    ADX: 12.4+DI: 21.2-DI: 20.6

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down88.0
    PSAR$1.10

    Bollinger Bands

    Upper Band$1.26
    Lower Band$0.82
    %B Position4254%(Upper)
    Band Width0.35

    RSI (14-Day)

    Neutral
    39.5

    Momentum Oscillators

    Stoch %K41.7
    Stoch %D30.2
    Williams %R-55.3
    ROC (10d)N/A
    MomentumN/A
    CCI (20d)-40.2
    MFI (14d)73.2

    Volatility Measures

    ATR (14d)$0.13(13.3%)
    StdDev (20d)0.11
    Hist Vol107.6%(High)

    Volume Flow

    VWAP$0.99
    OBV15.5M
    AD Line-10.6M
    CMF (20d)-0.153

    Volume Metrics

    Avg Vol (20d)227.7K
    Vol Ratio0.5x(Low)
    VWMA (20d)$1.02

    Pivot Points

    R3$1.29
    R2$1.19
    R1$1.11
    Pivot Point$1.01
    S1$0.93
    S2$0.83
    S3$0.75

    Advanced Oscillators

    TSI-29.11
    Ultimate Osc45.7
    KST-246.51

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$2,134$0$0$0$2,768$0
    Cost of Revenue$0$0$555$0$0$0$1,067$0$0$0$597$0
    Gross Profit$0$0$-555$0$0$0$1,067$0$0$0$2,171$0
    Operating Expenses$3.34M$2.51M$3.07M$2.73M$3.73M$3.93M$4.28M$2.46M$2.47M$1.76M$1.26M$1.14M
    R&D$705,151$771,508$666,323$688,465$1.08M$1.67M$1.54M$784,646$1.25M$629,025$361,127$243,948
    SG&A$2.63M$1.74M$2.40M$2.04M$2.66M$2.25M$2.74M$1.67M$1.21M$1.13M$902,108$898,051
    Operating Income$-3,340,400$-2,514,378$-3,065,107$-2,733,803$-3,734,291$-3,927,976$-4,278,428$-2,459,958$-2,466,618$-1,755,615$-1,263,831$-1,142,596
    Interest Income$17,835$17,838$26,117$48,098$67,004$82,596$91,159$52,129$73,636$92,327$119,771$106,145
    Interest Expense$0$0$0$0$0$0$0$0$0$0$3,534$0
    Income Before Tax$-3,322,565$-2,496,540$-3,038,990$-2,685,705$-3,667,287$-3,845,380$-4,187,269$-2,407,829$-2,392,982$-1,663,288$-1,130,493$-1,036,451
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,322,565$-2,496,540$-3,038,990$-2,685,705$-3,667,287$-3,845,380$-4,187,269$-2,407,829$-2,392,982$-1,663,288$-1,144,060$-1,036,451
    EBITDA$-3,339,896$-2,513,823$-3,064,552$-2,733,402$-3,733,890$-3,922,459$-4,278,021$-2,459,552$-2,466,148$-1,755,018$-1,249,667$-1,141,999
    EBIT$-3,340,400$-2,514,378$-3,065,107$-2,733,803$-3,734,291$-3,927,976$-4,278,428$-2,459,958$-2,466,618$-1,755,615$-1,250,264$-1,142,596
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CVKD

    News

    Cadrenal Therapeutics evaluating strategic options

    Cadrenal Therapeutics, a Ponte Vedra Beach-based pharmaceutical company, announced a strategic review process to explore opportunities including licensing, asset sales...

    Jacksonville Daily Record•10/15/26•Neutral

    Cadrenal Therapeutics (CVKD) director gets 75,000 options, immediately exercisable at $0.91.

    Cadrenal Therapeutics director Glynn Wilson received 75,000 stock options on October 9, 2026, which were immediately exercisable at an exercise price of $0.91 per share. The options were granted under the company's 2022...

    Stock Titan•10/14/26•Neutral

    Form 4 Cadrenal Therapeutics Inc: Jeffrey Scott Cole (COO) For: 9 October

    This article reports on a Form 4 filing for Cadrenal Therapeutics Inc, detailing an insider transaction by Chief Operating Officer Jeffrey Scott Cole on October 9. The report serves as a brief notification of the filing...

    Investing.com Nigeria•10/14/26•Neutral

    Form 4 Cadrenal Therapeutics Inc: Quang X. Pham (Director, 10% Owner, Chairman and CEO) For: 9 October

    This article reports on a Form 4 filing for Cadrenal Therapeutics Inc., indicating that Quang X. Pham, who holds positions as Director, 10% Owner, Chairman, and CEO...

    Investing.com Nigeria•10/13/26•Neutral

    Form 4 Cadrenal Therapeutics Inc: John Raymond Murphy (Director) For: 9 October

    This article reports a Form 4 filing for Cadrenal Therapeutics Inc., indicating a transaction made by John Raymond Murphy, a director of the company...

    Investing.com India•10/13/26•Neutral

    CVKD Valuation and Fair Value

    P/E
    -0.2x
    P/B
    0.7x
    See GNG's fair value

    CVKD Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -275.2%

    CVKD Competitors

    CompanyTicker
    60 Degrees Pharmaceuticals, Inc. Common StockSXTP
    Mustang Bio IncMBIO
    Clearmind Medicine Inc. Common SharesCMND
    GRI Bio Inc.GRI
    Calidi Biotherapeutics Inc.CLDI
    XORTX Therapeutics IncXRTX
    IO Biotech IncIOBT
    Ridgetech, Inc.RDGT

    Sector: Healthcare

    CVKD Bull Case vs Bear Case

    Bear case

    • CVKD beat EPS estimates in 37.5% of its last 8 reported quarters.

    CVKD Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -202.5%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.94
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About CVKD

    Does CVKD pay dividends?

    Cadrenal Therapeutics, Inc. Common Stock (CVKD) does not currently pay a regular dividend.

    What is CVKD's market cap?

    Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a market capitalization of $3.09M with a current stock price of $0.97.

    Related stocks

    Sector: Healthcare

    All stocks starting with C

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In